** Shares of drug developer Ideaya Biosciences IDYA.O fall 4.6% to $20.94

** Co reports Q4 net loss of $130.3 million compared with net loss of $34.0 million a year ago

** Collaboration revenue for the quarter was $7 million compared to $3.9 million a year earlier

** Co received milestone payment from GSK GSK.L

** As of December 31, co had cash, cash equivalents and marketable securities of about $1.1 billion, compared to $632.6 million a year earlier

** Separately, co entered into an additional clinical study collaboration and supply agreement with Gilead Sciences GILD.O to test IDYA's experimental drug, IDE397, in combination with GILD's trodelvy to treat a type of lung cancer

** In the last 12 months, IDYA has fallen ~53%

(Reporting by Siddhi Mahatole)

((siddhiprabhanjan.mahatole@thomsonreuters.com))